×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
返回 Agenda
Session 2: Health Canada Policy Priorities: Regulatory Review of Drugs/Devices, Cannabis, and the Controlled Drugs and Substance Strategy
Session Chair(s)
Marilena Bassi, MA
Senior Executive Director, Therapeutic Products Directorate
Health Canada, Canada
Senior officials from Health Canada will discuss current Departmental policy and regulatory priorities including initiatives to modernize regulatory review processes, the proposed legalization of cannabis and the federal government’s renewal of the controlled drugs and substance strategy.
Speaker(s)
Overview of Health Canada’s Regulatory Review of Drugs and Devices
Evelyn Soo, PhD, MS
Health Canada, Canada
Director, Bureau of Gastroenterology, Infection and Viral Diseases, HPFB
Proposed Cannabis Legalization
Chris Rose
Health Canada, Canada
Director, Cannabis Legalization and Regulation Branch
Updating the Controlled Drugs and Substances Strategy
Kirsten Mattison
Health Canada, Canada
Director of Drug Policy and Science
Panel Discussion
All Session Speakers, United States